Company intelligence / Profile preview
Modalis Therapeutics
Tokyo, Tokyo Metropolis, Japanmodalistx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Modalis Therapeutics has developed a proprietary epigenome editing technology called CRISPR-GNDM®, which allows for precise control of gene expression without altering the DNA sequence. The company’s programs are focused on rare genetic disorders and remain at the pre-clinical stage as of 2024[1][3].
- Therapeutic areas
- Rare Diseases
- Modalities
- Gene therapyCRISPR-based therapyEpigenome editing
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Beyond the preview
Go deeper on Modalis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Modalis Therapeutics.